Oncology/Immuno-oncology Portfolio
Various Cancers
Key Facts
About MSD
MSD Ireland is a cornerstone of Merck & Co.'s global network, serving as a premier European hub for R&D and manufacturing across biologics, small molecules, and vaccines. With over 3,600 employees across eight strategic sites and approximately $3.5 billion invested in the last 3.5 years, it is a top-tier contributor to Ireland's life sciences economy. The subsidiary's strategy is deeply integrated with the parent company's focus on scientific excellence, pipeline commercialization, and expanding global access to critical therapies.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| LADR Platform | LadRx | Preclinical |
| Zip-Code Library for Oncology | Kodikaz Therapeutic Solutions | Pre-clinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| Max Access Solutions (with The Max Foundation) | Tanner Pharma Group | N/A (Donation/Distribution Program) |
| Oncology Immunotherapy Programs | Therapeutic Solutions International | Pre-clinical |
| CPA Platform in Oncology | InnoSIGN | Development |
| Oncology Services | Transcure Bioservices | Preclinical |
| Oncology R&D | Orion Pharma | Not Specified |